Literature DB >> 3121940

Plasma exudation and asthma.

C G Persson1.   

Abstract

Several pieces of evidence support the view that exudation of plasma into the airway wall and into the airway lumen occurs in asthma. Vascular leakage of plasma results from inflammatory mediator-induced separation of endothelial cells in postcapillary venules belonging to the tracheobronchial circulation. Whereas proposed mediators of asthma induce reversible leakage, several antiasthma drugs exhibit antileakage effects in animals and humans. Potential consequences of plasma exudation are many. Mucosal/submucosal edema might contribute to airway hyperresponsiveness. Plasma exudate in the airway lumen in asthma may contribute to sloughing of epithelium, impairment of mucociliary transport, narrowing of small airways, and mucus plug formation. Exuded plasma may cause airway inflammation and constriction because of its content of powerful mediators, and chemoattractant factors and plasma proteins may condition the inflammatory cells abundant in asthmatic airways to release mediators in response to stimuli that otherwise would be innocuous to the cells. It is concluded that inflammatory stimulus-induced increase in macromolecular permeability of the tracheobronchial microvasculature and mucosa may be a significant pathogenetic mechanism in asthma and that the postcapillary venular endothelium and airway epithelium that regulate leakage of plasma are important effector cells in this disease.

Entities:  

Mesh:

Year:  1988        PMID: 3121940      PMCID: PMC7100194          DOI: 10.1007/bf02714025

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  102 in total

1.  Some properties of the iota-toxin of Clostridium welchii, including its action on capillary permeability.

Authors:  J P CRAIG; A A MILES
Journal:  J Pathol Bacteriol       Date:  1961-04

2.  Enhancement of the viscosity of mucin by serum albumin.

Authors:  S J List; B P Findlay; G G Forstner; J F Forstner
Journal:  Biochem J       Date:  1978-11-01       Impact factor: 3.857

3.  Intravital and electron microscopic study of bradykinin-induced vascular permeability changes using FITC-dextran as a tracer.

Authors:  D Hulström; E Svensjö
Journal:  J Pathol       Date:  1979-11       Impact factor: 7.996

4.  Control of vascular permeability by polymorphonuclear leukocytes in inflammation.

Authors:  C V Wedmore; T J Williams
Journal:  Nature       Date:  1981-02-19       Impact factor: 49.962

5.  Effect of bronchial lavage volume on cellular and protein recovery.

Authors:  S Lam; J C Leriche; K Kijek; D Phillips
Journal:  Chest       Date:  1985-12       Impact factor: 9.410

6.  Effects of hemodynamic edema formation on peripheral vs. central airway mechanics.

Authors:  M Ishii; N Matsumoto; T Fuyuki; W Hida; M Ichinose; H Inoue; T Takishima
Journal:  J Appl Physiol (1985)       Date:  1985-11

7.  Effect of fibrin degradation products on microvascular permeability.

Authors:  B Gerdin; T Saldeen
Journal:  Thromb Res       Date:  1978-12       Impact factor: 3.944

8.  Studies on inflammation. Ultrastructure of the prolonged vascular response induced by Clostridium oedematiens toxin.

Authors:  R S Cotran
Journal:  Lab Invest       Date:  1967-07       Impact factor: 5.662

9.  interactions between histamine and bradykinin assessed by continuous recording of increased vascular permeability.

Authors:  A Baumgarten; G J Melrose; W J Vagg
Journal:  J Physiol       Date:  1970-07       Impact factor: 5.182

10.  Protein permeability in the adult respiratory distress syndrome. Loss of size selectivity of the alveolar epithelium.

Authors:  J F Holter; J E Weiland; E R Pacht; J E Gadek; W B Davis
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

View more
  13 in total

1.  The use of the nose to study the inflammatory response of the respiratory tract.

Authors:  C G Persson; C Svensson; L Greiff; M Anderson; P Wollmer; U Alkner; I Erjefält
Journal:  Thorax       Date:  1992-12       Impact factor: 9.139

2.  Reversibility and reproducibility of histamine induced plasma leakage in nasal airways.

Authors:  C Svensson; C R Baumgarten; U Pipkorn; U Alkner; C G Persson
Journal:  Thorax       Date:  1989-01       Impact factor: 9.139

3.  In vitro modulation of the eosinophil-dependent enhancement of the permeability of the bronchial mucosa.

Authors:  C A Herbert; D Edwards; J R Boot; C Robinson
Journal:  Br J Pharmacol       Date:  1991-10       Impact factor: 8.739

Review 4.  Potassium channels and airway function: new therapeutic prospects.

Authors:  J L Black; P J Barnes
Journal:  Thorax       Date:  1990-03       Impact factor: 9.139

5.  Effects and interactions of sensory neuropeptides on airway microvascular leakage in guinea-pigs.

Authors:  D F Rogers; M G Belvisi; B Aursudkij; T W Evans; P J Barnes
Journal:  Br J Pharmacol       Date:  1988-12       Impact factor: 8.739

Review 6.  Humoral First-Line Mucosal Innate Defence in vivo.

Authors:  Carl Persson
Journal:  J Innate Immun       Date:  2020-03-23       Impact factor: 7.349

7.  Adding salmeterol to an inhaled corticosteroid: long term effects on bronchial inflammation in asthma.

Authors:  J G Koopmans; R Lutter; H M Jansen; J S van der Zee
Journal:  Thorax       Date:  2006-01-31       Impact factor: 9.139

8.  The effects of formoterol on plasma exudation produced by a localized acute inflammatory response to bradykinin in the tracheal mucosa of rats in vivo.

Authors:  S R O'Donnell; G P Anderson
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

9.  Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor.

Authors:  D Raeburn; S L Underwood; S A Lewis; V R Woodman; C H Battram; A Tomkinson; S Sharma; R Jordan; J E Souness; S E Webber
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

10.  Histamine-induced airway mucosal exudation of bulk plasma and plasma-derived mediators is not inhibited by intravenous bronchodilators.

Authors:  C Svensson; U Alkner; U Pipkorn; C G Persson
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.